Cite
HARVARD Citation
Yap, T. et al. (2022). IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer. Journal for immunotherapy of cancer. 10 (3), p. . [Online].